1. Phylogeny  
Glycogen synthase kinase‐3 beta (GSK3B, UniProt P49841) is a highly conserved serine/threonine protein kinase found in all eukaryotes. Orthologs of GSK3B have been identified from yeast and plants through invertebrates such as Drosophila—with the Drosophila homologue commonly known as shaggy—to mammals, where two closely related isoforms exist: GSK‐3α and GSK‐3β. Both isoforms share a high degree of sequence conservation in their catalytic domains (greater than 90% identity), although overall sequence identity is approximately 85% due to differences in regulatory regions outside the kinase core (ali2001glycogensynthasekinase3 pages 2-3, kaidanovichbeilin2011gsk3functionalinsights pages 1-2). Phylogenetic analysis, as reported in earlier large‐scale kinase surveys, places GSK‐3 within the CMGC group of kinases, an evolutionarily ancient family whose origin can be traced back to the last eukaryotic common ancestor. This evolutionary conservation underscores the fundamental roles of GSK‐3B in cellular signaling across species and highlights its participation in key regulatory networks such as those governing metabolism and cell fate decisions (ali2001glycogensynthasekinase3 pages 3-4, kaidanovichbeilin2011gsk3functionalinsights pages 1-2). The presence of two isoforms in vertebrates suggests a gene duplication event early in metazoan evolution, with subsequent divergence allowing for overlapping yet distinct regulatory roles in various tissues. Notably, while both isoforms occupy central positions in signaling pathways such as Wnt/β‐catenin, the beta isoform is frequently the subject of detailed biochemical and structural studies because of its involvement in critical physiological processes such as glucose homeostasis and neuronal function (ali2001glycogensynthasekinase3 pages 2-3).

2. Reaction Catalyzed  
GSK‐3β catalyzes the transfer of the γ‐phosphate from ATP to the hydroxyl group of serine or threonine residues on substrate proteins, thereby converting ATP to ADP and yielding a phosphorylated protein along with a proton (ali2001glycogensynthasekinase3 pages 2-3). The reaction mechanism is typically dependent on a “priming” event: substrates of GSK‐3β are usually pre‐phosphorylated at a serine or threonine residue four amino acids downstream (C‐terminal) of the target phosphorylation site. This priming phosphorylation creates a docking site that is recognized by GSK‐3β’s primed‐substrate binding pocket, ensuring specificity in phosphorylation events (beurel2015glycogensynthasekinase3 pages 10-12). Thus, the overall chemical reaction can be summarized as follows: ATP + [protein]–(OH) → ADP + [protein]–(O‑PO3²⁻) + H⁺, with substrate recognition intricately linked to the presence of a pre‐existing phosphate group on the substrate (ali2001glycogensynthasekinase3 pages 11-12).

3. Cofactor Requirements  
The enzymatic activity of GSK‐3β is strictly dependent on the presence of divalent metal ions. Magnesium ions (Mg²⁺) serve as the primary cofactor required for the coordination of ATP within the kinase’s active site, enabling the proper alignment of the γ‐phosphate for transfer to the substrate (ali2001glycogensynthasekinase3 pages 2-3). Although Mg²⁺ is the predominant cofactor, in some kinase reactions Mn²⁺ may also support catalytic activity; however, the physiological relevance of this substitution remains secondary to Mg²⁺ dependency. This requirement for Mg²⁺ is consistent with the typical cofactor needs of most serine/threonine kinases, underlining the common mechanistic features shared among members of the kinase family (piretti2019structuralandbiophysical pages 11-14).

4. Substrate Specificity  
GSK‐3β exhibits a distinct substrate specificity characterized by its preference for phosphorylating serine/threonine residues that are embedded within a defined consensus motif. The majority of its substrates require a “priming” phosphorylation at a serine or threonine residue located four amino acids C‐terminal to the target site, typically following a motif of the form S/T–X–X–X–pS/pT (ali2001glycogensynthasekinase3 pages 2-3, beurel2015glycogensynthasekinase3 pages 2-4). This mechanism ensures that GSK‐3β predominantly phosphorylates substrates that have already been modified by another kinase, effectively integrating signals from upstream pathways. Examples of substrates include glycogen synthase (GYS1 and GYS2), whose phosphorylation results in its inhibition and a consequent reduction in glycogen synthesis in skeletal muscle (ali2001glycogensynthasekinase3 pages 11-12); β‐catenin, which upon phosphorylation is targeted for degradation, thereby modulating the Wnt signaling pathway (ali2001glycogensynthasekinase3 pages 11-12, beurel2015glycogensynthasekinase3 pages 2-4); and components involved in the control of protein synthesis such as eIF2B (ali2001glycogensynthasekinase3 pages 11-12). In addition, substrates such as APC, AXIN1, CRMP2 (DPYSL2), the transcription factor JUN, NFAT, and tau (MAPT) have been identified as targets, highlighting the extensive range of cellular processes regulated by GSK‐3β. The enzyme’s active site and a dedicated priming phosphate binding pocket, formed by conserved basic residues such as Arg96, Arg180, and Lys205, are critical for recognizing and accommodating the phosphorylated residue in the substrate, thereby directing efficient catalysis (kaidanovichbeilin2011gsk3functionalinsights pages 7-9, ali2001glycogensynthasekinase3 pages 11-12).

5. Structure  
GSK‐3β is organized into a central catalytic domain flanked by regions that contribute to its regulation and substrate specificity. The three-dimensional structure of GSK‐3β reveals an architecture common to many protein kinases, comprising a small N‐terminal lobe that contains predominantly β‐sheet structures and a larger C‐terminal lobe primarily composed of α‐helices; the two lobes together form an active site cleft wherein ATP binds (bhat2003structuralinsightsand pages 9-9, kaidanovichbeilin2011gsk3functionalinsights pages 6-7). Within this cleft lies a glycine‐rich loop and hinge region critical for orienting ATP, and an elongated ATP‐binding pocket contributes to the kinase’s catalytic efficiency and aids in inhibitor design. A distinctive structural feature of GSK‐3β is the substrate recognition domain that binds to the priming phosphate present on substrates. This pocket, which is formed by several conserved basic residues (including Arg96, Arg180, and Lys205), is essential for positioning substrates for phosphorylation in accordance with the consensus S/T–X–X–X–pS/pT motif (piretti2019structuralandbiophysical pages 11-14, kaidanovichbeilin2011gsk3functionalinsights pages 6-7). In addition to the catalytic core, GSK‐3β contains regulatory sites; the N-terminal serine-9 is a key inhibitory phosphorylation site that, when modified, induces a conformational change acting as a pseudosubstrate in the active site, while phosphorylation of tyrosine-216 within the activation loop is associated with full enzymatic activity (beurel2015glycogensynthasekinase3 pages 28-29, bhat2003structuralinsightsand pages 1-2). Other structural determinants include a conserved ATP-binding motif with key hydrophobic residues such as Val135 and Leu132 that contribute to ligand-binding specificity, and the overall conformation exhibits features, such as a stabilized hydrophobic spine, that are critical for kinase activity (bhat2003structuralinsightsand pages 9-9, ali2001glycogensynthasekinase3 pages 3-4). These structures have been elucidated by crystallographic techniques and provide a framework for the rational design of selective inhibitors targeting GSK‐3β.

6. Regulation  
GSK‐3β is regulated by a complex interplay of post‐translational modifications, protein–protein interactions, and subcellular localization changes. One of the best‐characterized regulatory mechanisms is inhibitory phosphorylation at the conserved N‐terminal serine-9. Upstream kinases such as protein kinase B (Akt), protein kinase A (PKA), protein kinase C (PKC), and p70 S6 kinase phosphorylate this residue in response to extracellular signals like insulin and growth factors, leading to the formation of an autoinhibitory conformation that occludes the substrate binding site (ali2001glycogensynthasekinase3 pages 11-12, beurel2015glycogensynthasekinase3 pages 18-20). In contrast, phosphorylation at tyrosine-216 within the activation loop, which can occur via autophosphorylation or through the actions of Src family kinases, is necessary for full kinase activity and helps maintain a basal level of catalytic function (beurel2015glycogensynthasekinase3 pages 6-7, kaidanovichbeilin2011gsk3functionalinsights pages 18-19). In addition to these phosphorylation events, GSK‐3β is regulated by its incorporation into protein complexes. For example, its association with the scaffold protein Axin in the Wnt/β‐catenin destruction complex not only facilitates the phosphorylation of β‐catenin but also shields portions of the kinase from inhibitory modifications, thereby ensuring context‐dependent activity (beurel2015glycogensynthasekinase3 pages 29-31, ali2001glycogensynthasekinase3 pages 11-12). Interaction with regulatory proteins, such as FRAT, further modulates GSK‐3β substrate specificity and can alter its subcellular distribution; this allows the kinase to participate in discrete signaling events even in the face of global inhibitory signals. Inhibitors such as lithium exert their effects both by directly competing with magnesium ions at the ATP binding site and by indirectly enhancing serine-9 phosphorylation, thus lowering the overall kinase activity (beurel2015glycogensynthasekinase3 pages 18-20, domoto2020glycogensynthasekinase pages 1-3). Overall, these multilayered regulatory mechanisms finely tune GSK‐3β activity to meet the dynamic signaling requirements of the cell.

7. Function  
GSK‐3β plays central roles in a broad spectrum of cellular processes, reflecting its status as a constitutively active kinase that acts as a negative regulator under many physiological conditions. In the context of glucose metabolism, GSK‐3β phosphorylates and inactivates glycogen synthase (GYS1 or GYS2), thereby diminishing glycogen synthesis in skeletal muscle and liver and modulating insulin responsiveness (ali2001glycogensynthasekinase3 pages 11-12). In addition, GSK‐3β is a critical regulator of the Wnt/β‐catenin signaling pathway. By phosphorylating β‐catenin and targeting it for ubiquitination and proteasomal degradation, GSK‐3β exerts control over gene expression programs that govern cell proliferation, differentiation, and embryonic patterning (ali2001glycogensynthasekinase3 pages 11-12, beurel2015glycogensynthasekinase3 pages 2-4). Furthermore, GSK‐3β phosphorylates a variety of transcription factors—including JUN, NFAT, and CREB—as well as structural proteins such as Tau. The phosphorylation of tau by GSK‐3β can lead to the formation of neurofibrillary tangles, providing a molecular link to neurodegenerative conditions such as Alzheimer’s disease (ali2001glycogensynthasekinase3 pages 11-12, beurel2015glycogensynthasekinase3 pages 37-39). Beyond these well‐established roles, GSK‐3β is involved in the regulation of protein synthesis through its control of eukaryotic initiation factor 2B (eIF2B), thereby affecting overall rates of translation. Diverse substrates ranging from components of the microtubule network (e.g., CRMP2/DPYSL2) to proteins involved in cell cycle regulation have been ascribed to GSK‐3β, underscoring its importance in both metabolic and proliferative pathways (ali2001glycogensynthasekinase3 pages 11-12, beurel2015glycogensynthasekinase3 pages 28-29). This extensive substrate repertoire allows GSK‐3β to coordinate a variety of signaling cascades in a cell type–specific manner. Ubiquitously expressed, GSK‐3β exerts its functions in tissues ranging from skeletal muscle—where it influences insulin sensitivity—to the brain, where its activity is linked to neuronal plasticity and psychiatric disorders. The kinase’s regulation of transcription factors and its involvement in apoptosis further augment its role in maintaining cellular homeostasis, while its integration in feedback loops makes it a pivotal point for signal integration in both normal physiology and pathophysiological states (beurel2015glycogensynthasekinase3 pages 31-32, liu2018glycogensynthasekinase‐3 pages 1-3).

8. Other Comments  
Given its central regulatory role, GSK‐3β has emerged as an attractive therapeutic target for a range of diseases. Pharmacological inhibition of GSK‐3β—exemplified by agents such as lithium and the selective small-molecule inhibitor AR-A014418—has been extensively studied in the context of bipolar disorder, Alzheimer’s disease, and certain cancers (bhat2003structuralinsightsand pages 9-9, mccubrey2014gsk3aspotential pages 18-19). In addition to its classical functions in metabolism and signaling, GSK‐3β also plays roles in modulating RNA processing by phosphorylating splicing factors and other RNA-binding proteins, thereby influencing alternative splicing events and gene expression patterns (liu2018glycogensynthasekinase‐3 pages 27-29). The dual-mode inhibition by lithium—both by competing with magnesium ions at the ATP-binding pocket and by enhancing inhibitory serine-9 phosphorylation—highlights the complex regulatory potential of therapeutic compounds targeting GSK‐3β (beurel2015glycogensynthasekinase3 pages 18-20). Dysregulation of GSK‐3β activity has been implicated in diverse pathological conditions, including insulin resistance, neurodegeneration (due to aberrant tau phosphorylation), and oncogenesis through effects on β‐catenin and other substrates. The development of allosteric inhibitors and inhibitors that exploit subtle structural differences in the ATP-binding region represents a promising direction to achieve greater specificity. Overall, the continuous efforts to design potent and selective inhibitors underscore the importance of GSK‐3β as a multifunctional kinase whose dysfunction is associated with significant human diseases (domoto2020glycogensynthasekinase pages 20-22, wagner2018exploitinganaspglu pages 23-25).

9. References  
1. Ali, A., Hoeflich, K. P., & Woodgett, J. R. "Glycogen synthase kinase-3: properties, functions, and regulation." Chemical Reviews, 101:2527-2540, Jul 2001. DOI: 10.1021/cr000110o (ali2001glycogensynthasekinase3 pages 1-2, ali2001glycogensynthasekinase3 pages 2-3, ali2001glycogensynthasekinase3 pages 3-4, ali2001glycogensynthasekinase3 pages 11-12).  
2. Beurel, E., Grieco, S. F., & Jope, R. S. "Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases." Pharmacology & Therapeutics, 148:114-131, Apr 2015. DOI: 10.1016/j.pharmthera.2014.11.016 (beurel2015glycogensynthasekinase3 pages 1-2, beurel2015glycogensynthasekinase3 pages 2-4, beurel2015glycogensynthasekinase3 pages 7-9, beurel2015glycogensynthasekinase3 pages 10-12, beurel2015glycogensynthasekinase3 pages 18-20, beurel2015glycogensynthasekinase3 pages 28-29, beurel2015glycogensynthasekinase3 pages 29-31, beurel2015glycogensynthasekinase3 pages 31-32, beurel2015glycogensynthasekinase3 pages 33-35, beurel2015glycogensynthasekinase3 pages 37-39, beurel2015glycogensynthasekinase3 pages 39-40, beurel2015glycogensynthasekinase3 pages 40-44).  
3. Bhat, R., et al. "Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418." Journal of Biological Chemistry, 278:45937-45945, Nov 2003. DOI: 10.1074/jbc.m306268200 (bhat2003structuralinsightsand pages 1-2, bhat2003structuralinsightsand pages 9-9).  
4. Borden, B. A., et al. "The landscape of glycogen synthase kinase-3 beta genomic alterations in cancer." Molecular Cancer Therapeutics, 20:183-190, Jan 2021. DOI: 10.1158/1535-7163.mct-20-0497 (borden2021thelandscapeof pages 21-25).  
5. Cormier, K. W., et al. "Interactomes of glycogen synthase kinase-3 isoforms." Journal of Proteome Research, 22:977-989, Feb 2023. DOI: 10.1021/acs.jproteome.2c00825 (cormier2023interactomesofglycogen pages 1-2, cormier2023interactomesofglycogen pages 9-10, cormier2023interactomesofglycogen pages 12-13).  
6. Ding, L., & Billadeau, D. D. "Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer." Expert Opinion on Therapeutic Targets, 24:417-426, Mar 2020. DOI: 10.1080/14728222.2020.1743681 (ding2020glycogensynthasekinase3β pages 7-11).  
7. Domoto, T., et al. "Glycogen synthase kinase 3β in cancer biology and treatment." Cells, 9:1388, Jun 2020. DOI: 10.3390/cells9061388 (domoto2020glycogensynthasekinase pages 1-3, domoto2020glycogensynthasekinase pages 20-22).  
8. Ghaderi, S., et al. "Role of glycogen synthase kinase following myocardial infarction and ischemia–reperfusion." Apoptosis, 22:887-897, Apr 2017. DOI: 10.1007/s10495-017-1376-0 (ghaderi2017roleofglycogen pages 1-2).  
9. Kaidanovich-Beilin, O., & Woodgett, J. R. "Gsk-3: functional insights from cell biology and animal models." Frontiers in Molecular Neuroscience, Nov 2011. DOI: 10.3389/fnmol.2011.00040 (kaidanovichbeilin2011gsk3functionalinsights pages 1-2, kaidanovichbeilin2011gsk3functionalinsights pages 4-6, kaidanovichbeilin2011gsk3functionalinsights pages 6-7, kaidanovichbeilin2011gsk3functionalinsights pages 7-9, kaidanovichbeilin2011gsk3functionalinsights pages 9-10, kaidanovichbeilin2011gsk3functionalinsights pages 17-18, kaidanovichbeilin2011gsk3functionalinsights pages 18-19, kaidanovichbeilin2011gsk3functionalinsights pages 22-23, kaidanovichbeilin2011gsk3functionalinsights pages 23-24, kaidanovichbeilin2011gsk3functionalinsights pages 24-25, kaidanovichbeilin2011gsk3functionalinsights pages 25-25).  
10. Liu, X., & Klein, P. S. "Glycogen synthase kinase‐3 and alternative splicing." WIREs RNA, Aug 2018. DOI: 10.1002/wrna.1501 (liu2018glycogensynthasekinase‐3 pages 1-3, liu2018glycogensynthasekinase‐3 pages 8-9, liu2018glycogensynthasekinase‐3 pages 27-29).  
11. McCubrey, J., et al. "Gsk-3 as potential target for therapeutic intervention in cancer." Oncotarget, 5:2881-2911, May 2014. DOI: 10.18632/oncotarget.2037 (mccubrey2014gsk3aspotential pages 1-3, mccubrey2014gsk3aspotential pages 3-4, mccubrey2014gsk3aspotential pages 4-5, mccubrey2014gsk3aspotential pages 12-13, mccubrey2014gsk3aspotential pages 18-19, mccubrey2014gsk3aspotential pages 19-20).  
12. Wagner, F. F., et al. "Exploiting an asp-glu 'switch' in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia." Science Translational Medicine, Mar 2018. DOI: 10.1126/scitranslmed.aam8460 (wagner2018exploitinganaspglu pages 23-25, wagner2018exploitinganaspglu pages 25-26).

References

1. (ali2001glycogensynthasekinase3 pages 11-12): Adnan Ali, Klaus P. Hoeflich, and James R. Woodgett. Glycogen synthase kinase-3: properties, functions, and regulation. Chemical Reviews, 101:2527-2540, Jul 2001. URL: https://doi.org/10.1021/cr000110o, doi:10.1021/cr000110o. This article has 567 citations and is from a highest quality peer-reviewed journal.

2. (ali2001glycogensynthasekinase3 pages 2-3): Adnan Ali, Klaus P. Hoeflich, and James R. Woodgett. Glycogen synthase kinase-3: properties, functions, and regulation. Chemical Reviews, 101:2527-2540, Jul 2001. URL: https://doi.org/10.1021/cr000110o, doi:10.1021/cr000110o. This article has 567 citations and is from a highest quality peer-reviewed journal.

3. (ali2001glycogensynthasekinase3 pages 3-4): Adnan Ali, Klaus P. Hoeflich, and James R. Woodgett. Glycogen synthase kinase-3: properties, functions, and regulation. Chemical Reviews, 101:2527-2540, Jul 2001. URL: https://doi.org/10.1021/cr000110o, doi:10.1021/cr000110o. This article has 567 citations and is from a highest quality peer-reviewed journal.

4. (beurel2015glycogensynthasekinase3 pages 18-20): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

5. (beurel2015glycogensynthasekinase3 pages 29-31): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

6. (beurel2015glycogensynthasekinase3 pages 39-40): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

7. (beurel2015glycogensynthasekinase3 pages 40-44): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

8. (beurel2015glycogensynthasekinase3 pages 7-9): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

9. (bhat2003structuralinsightsand pages 9-9): Ratan Bhat, Yafeng Xue, Stefan Berg, Sven Hellberg, Mats Ormö, Yvonne Nilsson, Ann-Cathrin Radesäter, Eva Jerning, Per-Olof Markgren, Thomas Borgegård, Martin Nylöf, Alfredo Giménez-Cassina, Félix Hernández, Jose J. Lucas, Javier Díaz-Nido, and Jesús Avila. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor ar-a014418. Journal of Biological Chemistry, 278:45937-45945, Nov 2003. URL: https://doi.org/10.1074/jbc.m306268200, doi:10.1074/jbc.m306268200. This article has 660 citations and is from a domain leading peer-reviewed journal.

10. (borden2021thelandscapeof pages 21-25): Brittany A. Borden, Yasmine Baca, Joanne Xiu, Fabio Tavora, Ira Winer, Benjamin A. Weinberg, Ari M. Vanderwalde, Sourat Darabi, W. Michael Korn, Andrew P. Mazar, Francis J. Giles, Lorin Crawford, Howard Safran, Wafik S. El-Deiry, and Benedito A. Carneiro. The landscape of glycogen synthase kinase-3 beta genomic alterations in cancer. Molecular Cancer Therapeutics, 20:183-190, Jan 2021. URL: https://doi.org/10.1158/1535-7163.mct-20-0497, doi:10.1158/1535-7163.mct-20-0497. This article has 11 citations and is from a peer-reviewed journal.

11. (cormier2023interactomesofglycogen pages 1-2): Kevin W. Cormier, Brett Larsen, Anne-Claude Gingras, and James R. Woodgett. Interactomes of glycogen synthase kinase-3 isoforms. Journal of Proteome Research, 22:977-989, Feb 2023. URL: https://doi.org/10.1021/acs.jproteome.2c00825, doi:10.1021/acs.jproteome.2c00825. This article has 15 citations and is from a peer-reviewed journal.

12. (ding2020glycogensynthasekinase3β pages 7-11): Li Ding and Daniel D. Billadeau. Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer. Expert Opinion on Therapeutic Targets, 24:417-426, Mar 2020. URL: https://doi.org/10.1080/14728222.2020.1743681, doi:10.1080/14728222.2020.1743681. This article has 42 citations and is from a peer-reviewed journal.

13. (domoto2020glycogensynthasekinase pages 1-3): Takahiro Domoto, Masahiro Uehara, Dilireba Bolidong, and Toshinari Minamoto. Glycogen synthase kinase 3β in cancer biology and treatment. Cells, 9:1388, Jun 2020. URL: https://doi.org/10.3390/cells9061388, doi:10.3390/cells9061388. This article has 99 citations and is from a peer-reviewed journal.

14. (domoto2020glycogensynthasekinase pages 20-22): Takahiro Domoto, Masahiro Uehara, Dilireba Bolidong, and Toshinari Minamoto. Glycogen synthase kinase 3β in cancer biology and treatment. Cells, 9:1388, Jun 2020. URL: https://doi.org/10.3390/cells9061388, doi:10.3390/cells9061388. This article has 99 citations and is from a peer-reviewed journal.

15. (ghaderi2017roleofglycogen pages 1-2): Shahrooz Ghaderi, N. Alidadiani, N. Dilaver, Hamid Reza Heidari, R. Parvizi, R. Rahbarghazi, J. Soleimanirad, and B. Baradaran. Role of glycogen synthase kinase following myocardial infarction and ischemia–reperfusion. Apoptosis, 22:887-897, Apr 2017. URL: https://doi.org/10.1007/s10495-017-1376-0, doi:10.1007/s10495-017-1376-0. This article has 45 citations and is from a peer-reviewed journal.

16. (kaidanovichbeilin2011gsk3functionalinsights pages 1-2): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

17. (kaidanovichbeilin2011gsk3functionalinsights pages 22-23): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

18. (kaidanovichbeilin2011gsk3functionalinsights pages 24-25): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

19. (kaidanovichbeilin2011gsk3functionalinsights pages 9-10): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

20. (mccubrey2014gsk3aspotential pages 12-13): J. McCubrey, L. Steelman, F. E. Bertrand, N. M. Davis, Melissa L. Sokolosky, Stephen L. Abrams, G. Montalto, Antonino B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z. Demidenko, L. Cocco, A. Martelli, and M. Cervello. Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5:2881-2911, May 2014. URL: https://doi.org/10.18632/oncotarget.2037, doi:10.18632/oncotarget.2037. This article has 580 citations and is from a poor quality or predatory journal.

21. (mccubrey2014gsk3aspotential pages 18-19): J. McCubrey, L. Steelman, F. E. Bertrand, N. M. Davis, Melissa L. Sokolosky, Stephen L. Abrams, G. Montalto, Antonino B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z. Demidenko, L. Cocco, A. Martelli, and M. Cervello. Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5:2881-2911, May 2014. URL: https://doi.org/10.18632/oncotarget.2037, doi:10.18632/oncotarget.2037. This article has 580 citations and is from a poor quality or predatory journal.

22. (mccubrey2014gsk3aspotential pages 3-4): J. McCubrey, L. Steelman, F. E. Bertrand, N. M. Davis, Melissa L. Sokolosky, Stephen L. Abrams, G. Montalto, Antonino B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z. Demidenko, L. Cocco, A. Martelli, and M. Cervello. Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5:2881-2911, May 2014. URL: https://doi.org/10.18632/oncotarget.2037, doi:10.18632/oncotarget.2037. This article has 580 citations and is from a poor quality or predatory journal.

23. (mccubrey2014gsk3aspotential pages 4-5): J. McCubrey, L. Steelman, F. E. Bertrand, N. M. Davis, Melissa L. Sokolosky, Stephen L. Abrams, G. Montalto, Antonino B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z. Demidenko, L. Cocco, A. Martelli, and M. Cervello. Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5:2881-2911, May 2014. URL: https://doi.org/10.18632/oncotarget.2037, doi:10.18632/oncotarget.2037. This article has 580 citations and is from a poor quality or predatory journal.

24. (piretti2019structuralandbiophysical pages 11-14): V Piretti. Structural and biophysical characterization of novel gsk-3β inhibitors. Unknown journal, Oct 2019. URL: https://doi.org/10.6092/unibo/amsdottorato/9103, doi:10.6092/unibo/amsdottorato/9103. This article has 0 citations.

25. (wagner2018exploitinganaspglu pages 23-25): Florence F. Wagner, Lina Benajiba, Arthur J. Campbell, Michel Weïwer, Joshua R. Sacher, Jennifer P. Gale, Linda Ross, Alexandre Puissant, Gabriela Alexe, Amy Conway, Morgan Back, Yana Pikman, Ilene Galinsky, Daniel J. DeAngelo, Richard M. Stone, Taner Kaya, Xi Shi, Matthew B. Robers, Thomas Machleidt, Jennifer Wilkinson, Olivier Hermine, Andrew Kung, Adam J. Stein, Damodharan Lakshminarasimhan, Michael T. Hemann, Edward Scolnick, Yan-Ling Zhang, Jen Q. Pan, Kimberly Stegmaier, and Edward B. Holson. Exploiting an asp-glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, Mar 2018. URL: https://doi.org/10.1126/scitranslmed.aam8460, doi:10.1126/scitranslmed.aam8460. This article has 96 citations and is from a highest quality peer-reviewed journal.

26. (wagner2018exploitinganaspglu pages 25-26): Florence F. Wagner, Lina Benajiba, Arthur J. Campbell, Michel Weïwer, Joshua R. Sacher, Jennifer P. Gale, Linda Ross, Alexandre Puissant, Gabriela Alexe, Amy Conway, Morgan Back, Yana Pikman, Ilene Galinsky, Daniel J. DeAngelo, Richard M. Stone, Taner Kaya, Xi Shi, Matthew B. Robers, Thomas Machleidt, Jennifer Wilkinson, Olivier Hermine, Andrew Kung, Adam J. Stein, Damodharan Lakshminarasimhan, Michael T. Hemann, Edward Scolnick, Yan-Ling Zhang, Jen Q. Pan, Kimberly Stegmaier, and Edward B. Holson. Exploiting an asp-glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, Mar 2018. URL: https://doi.org/10.1126/scitranslmed.aam8460, doi:10.1126/scitranslmed.aam8460. This article has 96 citations and is from a highest quality peer-reviewed journal.

27. (ali2001glycogensynthasekinase3 pages 1-2): Adnan Ali, Klaus P. Hoeflich, and James R. Woodgett. Glycogen synthase kinase-3: properties, functions, and regulation. Chemical Reviews, 101:2527-2540, Jul 2001. URL: https://doi.org/10.1021/cr000110o, doi:10.1021/cr000110o. This article has 567 citations and is from a highest quality peer-reviewed journal.

28. (beurel2015glycogensynthasekinase3 pages 1-2): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

29. (beurel2015glycogensynthasekinase3 pages 10-12): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

30. (beurel2015glycogensynthasekinase3 pages 2-4): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

31. (beurel2015glycogensynthasekinase3 pages 28-29): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

32. (beurel2015glycogensynthasekinase3 pages 31-32): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

33. (beurel2015glycogensynthasekinase3 pages 33-35): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

34. (beurel2015glycogensynthasekinase3 pages 37-39): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

35. (beurel2015glycogensynthasekinase3 pages 6-7): Eleonore Beurel, Steven F. Grieco, and Richard S. Jope. Glycogen synthase kinase-3 (gsk3): regulation, actions, and diseases. Pharmacology &amp; Therapeutics, 148:114-131, Apr 2015. URL: https://doi.org/10.1016/j.pharmthera.2014.11.016, doi:10.1016/j.pharmthera.2014.11.016. This article has 1880 citations.

36. (bhat2003structuralinsightsand pages 1-2): Ratan Bhat, Yafeng Xue, Stefan Berg, Sven Hellberg, Mats Ormö, Yvonne Nilsson, Ann-Cathrin Radesäter, Eva Jerning, Per-Olof Markgren, Thomas Borgegård, Martin Nylöf, Alfredo Giménez-Cassina, Félix Hernández, Jose J. Lucas, Javier Díaz-Nido, and Jesús Avila. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor ar-a014418. Journal of Biological Chemistry, 278:45937-45945, Nov 2003. URL: https://doi.org/10.1074/jbc.m306268200, doi:10.1074/jbc.m306268200. This article has 660 citations and is from a domain leading peer-reviewed journal.

37. (cormier2023interactomesofglycogen pages 12-13): Kevin W. Cormier, Brett Larsen, Anne-Claude Gingras, and James R. Woodgett. Interactomes of glycogen synthase kinase-3 isoforms. Journal of Proteome Research, 22:977-989, Feb 2023. URL: https://doi.org/10.1021/acs.jproteome.2c00825, doi:10.1021/acs.jproteome.2c00825. This article has 15 citations and is from a peer-reviewed journal.

38. (cormier2023interactomesofglycogen pages 9-10): Kevin W. Cormier, Brett Larsen, Anne-Claude Gingras, and James R. Woodgett. Interactomes of glycogen synthase kinase-3 isoforms. Journal of Proteome Research, 22:977-989, Feb 2023. URL: https://doi.org/10.1021/acs.jproteome.2c00825, doi:10.1021/acs.jproteome.2c00825. This article has 15 citations and is from a peer-reviewed journal.

39. (kaidanovichbeilin2011gsk3functionalinsights pages 17-18): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

40. (kaidanovichbeilin2011gsk3functionalinsights pages 18-19): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

41. (kaidanovichbeilin2011gsk3functionalinsights pages 23-24): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

42. (kaidanovichbeilin2011gsk3functionalinsights pages 25-25): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

43. (kaidanovichbeilin2011gsk3functionalinsights pages 4-6): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

44. (kaidanovichbeilin2011gsk3functionalinsights pages 6-7): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

45. (kaidanovichbeilin2011gsk3functionalinsights pages 7-9): Oksana Kaidanovich-Beilin and James Robert Woodgett. Gsk-3: functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, Nov 2011. URL: https://doi.org/10.3389/fnmol.2011.00040, doi:10.3389/fnmol.2011.00040. This article has 597 citations and is from a peer-reviewed journal.

46. (liu2018glycogensynthasekinase‐3 pages 1-3): Xiaolei Liu and Peter S. Klein. Glycogen synthase kinase‐3 and alternative splicing. WIREs RNA, Aug 2018. URL: https://doi.org/10.1002/wrna.1501, doi:10.1002/wrna.1501. This article has 32 citations.

47. (liu2018glycogensynthasekinase‐3 pages 27-29): Xiaolei Liu and Peter S. Klein. Glycogen synthase kinase‐3 and alternative splicing. WIREs RNA, Aug 2018. URL: https://doi.org/10.1002/wrna.1501, doi:10.1002/wrna.1501. This article has 32 citations.

48. (liu2018glycogensynthasekinase‐3 pages 8-9): Xiaolei Liu and Peter S. Klein. Glycogen synthase kinase‐3 and alternative splicing. WIREs RNA, Aug 2018. URL: https://doi.org/10.1002/wrna.1501, doi:10.1002/wrna.1501. This article has 32 citations.

49. (mccubrey2014gsk3aspotential pages 1-3): J. McCubrey, L. Steelman, F. E. Bertrand, N. M. Davis, Melissa L. Sokolosky, Stephen L. Abrams, G. Montalto, Antonino B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z. Demidenko, L. Cocco, A. Martelli, and M. Cervello. Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5:2881-2911, May 2014. URL: https://doi.org/10.18632/oncotarget.2037, doi:10.18632/oncotarget.2037. This article has 580 citations and is from a poor quality or predatory journal.

50. (mccubrey2014gsk3aspotential pages 19-20): J. McCubrey, L. Steelman, F. E. Bertrand, N. M. Davis, Melissa L. Sokolosky, Stephen L. Abrams, G. Montalto, Antonino B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z. Demidenko, L. Cocco, A. Martelli, and M. Cervello. Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5:2881-2911, May 2014. URL: https://doi.org/10.18632/oncotarget.2037, doi:10.18632/oncotarget.2037. This article has 580 citations and is from a poor quality or predatory journal.